Estrogen receptor β selective agonists reduce invasiveness of triple‑negative breast cancer cells

Hinsche,Oliver; Girgert,Rainer; Emons,Günter; Gründker,Carsten

doi:10.3892/ijo.2014.2778

Estrogen receptor β selective agonists reduce invasiveness of triple‑negative breast cancer cells

Authors:
- Oliver Hinsche
- Rainer Girgert
- Günter Emons
- Carsten Gründker
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Georg‑August University, Göttingen 37075, Germany
Published online on: November 25, 2014 https://doi.org/10.3892/ijo.2014.2778
Pages: 878-884

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis to bone is a frequent problem of advanced breast cancer. Particularly breast cancers, which do not express estrogen receptor α (ERα) and progesterone receptor (PR) and which have no overexpression of human epidermal growth factor receptor 2 (HER2), so‑called triple‑negative breast cancers (TNBCs), are considered as very aggressive and have a poor prognosis. Recently we have shown that breast cancer cell invasion was dramatically increased when co‑cultured with MG63 osteoblast‑like cells. Using this model we have now analyzed whether estrogen receptor β (ERβ) plays a role in TNBC cell invasion in vitro. ERα and ERβ protein expression was analyzed using western blot analysis. Invasion was quantified by assessment of TNBC cell migration rate through an artificial basement membrane in a modified Boyden chamber during co‑culture with MG63 osteoblast‑like cells. The effects of ERβ agonist treatment on CXC motif chemokine receptor 4 (CXCR4) protein expression during co‑culture with MG64 cells was quantified using western blot analysis. Proliferation was measured using alamarBlue assay. TNBC cell lines HCC1806 and HCC1937 showed no ERα but high ERβ protein expression. Cell invasion of HCC1806 and HCC1937 TNBC cells was significantly increased when co‑cultured with MG63 osteoblast‑like cells. Treatment with ERβ selective estrogen agonists liquiritigenin and ERB‑041 reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus. During co‑culture CXCR4 protein expression of TNBC cell lines HCC1806 and HCC1937 was significantly increased. Treatment with liquiritigenin resulted in a significant decrease of CXCR4 protein expression. Both ERβ agonists showed no effect on TNBC cell proliferation. Our findings suggest that ERβ plays a major role in TNBC invasion. Bone‑directed invasion can be inhibited by ERβ agonists.

View Figures

View References

1	Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB and Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 37:1217–1226. 2006. View Article : Google Scholar : PubMed/NCBI
2	Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
4	Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 13:1033–1067. 2006. View Article : Google Scholar : PubMed/NCBI
5	Tomin R and Donegan WL: Screening for recurrent breast cancer - its effectiveness and prognostic value. J Clin Oncol. 5:62–67. 1987.PubMed/NCBI
6	Schlappack OK, Baur M, Steger G, Dittrich C and Moser K: The clinical course of lung metastases from breast cancer. Klin Wochenschr. 66:790–795. 1988. View Article : Google Scholar : PubMed/NCBI
7	Selzner M, Morse MA, Vredenburgh JJ, Meyers WC and Clavien PA: Liver metastases from breast cancer: long-term survival after curative resection. Surgery. 127:383–389. 2000. View Article : Google Scholar : PubMed/NCBI
8	von Alten J, Fister S, Schulz H, et al: GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat. 100:13–21. 2006. View Article : Google Scholar : PubMed/NCBI
9	Olbrich T, Ziegler E, Türk G, Schubert A, Emons G and Gründker C: Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: evidence for a dose-window effect. Gynecol Oncol. 119:571–578. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lindberg K, Ström A, Lock JG, Gustafsson JA, Haldosén LA and Helguero LA: Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol. 222:156–167. 2010. View Article : Google Scholar
11	Marotti JD, Collins LC, Hu R and Tamimi RM: Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 23:197–204. 2010. View Article : Google Scholar
12	Chen JQ and Russo J: ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 1796:162–175. 2009.PubMed/NCBI
13	Sakamoto G and Honma N: Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer. Breast Cancer. 16:281–282. 2009. View Article : Google Scholar : PubMed/NCBI
14	Schmidt E, Haase M, Ziegler E, Emons G and Gründker C: Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells. Int J Gynecol Cancer. 24:210–217. 2014. View Article : Google Scholar : PubMed/NCBI
15	Girgert R, Emons G and Gründker C: Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat. 134:199–205. 2012. View Article : Google Scholar : PubMed/NCBI
16	Mersereau JE, Levy N, Staub RE, et al: Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol. 283:49–57. 2008. View Article : Google Scholar : PubMed/NCBI
17	Shanle EK, Hawse JR and Xu W: Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. Biochem Pharmacol. 82:1940–1949. 2011. View Article : Google Scholar : PubMed/NCBI
18	Liu Y, Xie S, Wang Y, Luo K and Cai Y: Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells. Molecules. 17:7206–7216. 2012. View Article : Google Scholar : PubMed/NCBI
19	Chaudhary SC, Singh T, Talwelkar SS, et al: Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 7:186–198. 2014. View Article : Google Scholar
20	Samanta S, Sharma VM, Khan A and Mercurio AM: Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer. Oncogene. 31:4689–4697. 2012. View Article : Google Scholar : PubMed/NCBI
21	Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
22	Chu QD, Panu L, Holm NT, Li BD, Johnson LW and Zhang S: High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res. 159:689–695. 2010. View Article : Google Scholar
23	Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS and Richmond A: CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell. 25:566–582. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sun Y, Mao X, Fan C, et al: CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biol. 35:7765–7773. 2014. View Article : Google Scholar : PubMed/NCBI
25	Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L and Shim H: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65:967–971. 2005.PubMed/NCBI
26	Li HY, Ren GS and Tan JX: The effects of shRNA-CXCR4 on breast cancer cells migration and invasion. Sichuan Da Xue Xue Bao Yi Xue Ban. 40:393–397. 2009.(In Chinese). PubMed/NCBI